GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » Cyclically Adjusted Revenue per Share

Divi's Laboratories (NSE:DIVISLAB) Cyclically Adjusted Revenue per Share : ₹310.00 (As of Mar. 2025)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Divi's Laboratories's adjusted revenue per share for the three months ended in Mar. 2025 was ₹97.340. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹310.00 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-06-18), Divi's Laboratories's current stock price is ₹6538.00. Divi's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹310.00. Divi's Laboratories's Cyclically Adjusted PS Ratio of today is 21.09.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Divi's Laboratories was 21.51. The lowest was 17.69. And the median was 18.87.


Divi's Laboratories Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Divi's Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Divi's Laboratories Cyclically Adjusted Revenue per Share Chart

Divi's Laboratories Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 310.00

Divi's Laboratories Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 308.57 310.00

Competitive Comparison of Divi's Laboratories's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's Cyclically Adjusted PS Ratio falls into.


;
;

Divi's Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Divi's Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=97.34/157.5517*157.5517
=97.340

Current CPI (Mar. 2025) = 157.5517.

Divi's Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200703 0.000 48.581 0.000
200803 0.000 52.407 0.000
200903 0.000 56.615 0.000
201003 0.000 65.030 0.000
201103 0.000 70.768 0.000
201203 0.000 76.889 0.000
201303 0.000 85.687 0.000
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 37.479 111.317 53.046
201809 49.878 115.142 68.249
201812 51.237 115.142 70.109
201903 42.361 118.202 56.463
201906 43.794 120.880 57.080
201909 54.455 123.175 69.653
201912 52.609 126.235 65.660
202003 48.456 124.705 61.219
202006 65.201 127.000 80.886
202009 65.886 130.118 79.777
202012 64.100 130.889 77.157
202103 63.163 131.771 75.521
202106 73.870 134.084 86.799
202109 74.852 135.847 86.811
202112 93.928 138.161 107.111
202203 88.810 138.822 100.792
202206 84.932 142.347 94.004
202209 69.986 144.661 76.222
202212 64.524 145.763 69.743
202303 69.536 146.865 74.596
202306 66.975 150.280 70.216
202309 71.917 151.492 74.794
202312 69.951 152.924 72.068
202403 86.649 153.035 89.207
202406 79.794 155.789 80.697
202409 88.019 157.882 87.835
202412 87.406 158.323 86.980
202503 97.340 157.552 97.340

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Divi's Laboratories  (NSE:DIVISLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Divi's Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6538.00/310.00
=21.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Divi's Laboratories was 21.51. The lowest was 17.69. And the median was 18.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Divi's Laboratories Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Divi's Laboratories Business Description

Traded in Other Exchanges
Address
Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients with a predominance in exports. It also through its custom synthesis, supports pharma companies for their patented products business from gram scale requirements for clinical trials to launch as well as late life cycle management. Geographically, the company derives a majority of its revenue through exports to countries like the United States of America, Switzerland, and other countries.

Divi's Laboratories Headlines

No Headlines